1. A closer look at the companies moving COVID vaccines around the world — UK approves Pfizer's COVID-19 vaccine, putting pressure on FDA — Janssen buys eye disorder gene therapy asset from Hemera Biosciences — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Ozanimod - any opportunity or just a Biogen redux?

Discussion in 'Celgene' started by anonymous, Nov 13, 2018 at 6:07 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I'm in the space. Multiple award winner with experience with KOLs in my geography. Been in MS for 10+ years.

    I know several of your Otezla reps and they seem to enjoy the best culture in the industry, but I don't have dermatology or rheumatology experience. Will the MS reps be under the same leadership?

    I heard they are only considering Biogen reps, which would be a mistake. Is this accurate?
     

  2. anonymous

    anonymous Guest


    Get lost loser.
     
  3. anonymous

    anonymous Guest

    This drug is going to be a dog.
     
  4. anonymous

    anonymous Guest

    Keep wishing hater!
     
  5. anonymous

    anonymous Guest

    what are you talking about??? Drug isn’t even close to approval, and other MS drugs got the jump on us. It’s gonna be mediocre at best
     
  6. anonymous

    anonymous Guest

    well you clowns are posting, recruiting and hiring people TODAY for KOL liaison roles.
     
  7. anonymous

    anonymous Guest

    Let’s go Celgene!!
     
  8. anonymous

    anonymous Guest

    Yeah, medical liaisons, not reps. In case you are unaware, they are very different.
     
  9. anonymous

    anonymous Guest

  10. anonymous

    anonymous Guest

    What a F'ing idiot. The medical liaisons were hired long ago. They are currently in role and have been for some time.

    Go to Celgene's Career Page - they are recruiting COMMERICAL personnel for some sort of KOL Liaison.

    Dumb @ss.
     
  11. anonymous

    anonymous Guest


    This post isn’t too off base. All they could talk about was Ozanimod! Then the rejected fda mishap- boom ......silence
     
  12. anonymous

    anonymous Guest

    Yep. This drug will be an extreme niche with very few people on it. Reps will scramble for crumbs. Big time mutt!!!!
     
  13. anonymous

    anonymous Guest

    You can only wish! Au contraire
     
  14. anonymous

    anonymous Guest

    Keep wishinh, soon stock will be below 50